Subclinical Thyroid Disease

Clinical Applications

Nananda F. Col, Martin I. Surks, Gilbert H. Daniels

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Subclinical hypothyroidism and hyperthyroidism are diagnoses based on laboratory evaluation with few if any clinical signs or symptoms. Subclinical hypothyroidism is defined as an elevation in serum thyroid-stimulating hormone (TSH) above the upper limit of the reference range (0.45-4.5 mIU/L) with normal serum FT4 concentration; subclinical hyperthyroidism is defined as a decrease in serum TSH below the reference range with normal serum FT 4 and T3 concentrations. Though these conditions represent the earliest stages of thyroid dysfunction, the benefits of detecting and treating subclinical thyroid disease are not well established. Most persons found to have subclinical thyroid disease will have TSH values between 0.1 and 0.45 mIU/L or between 4.5 and 10 mIU/L, for which the benefits of treatment are not clearly established; treatment may be beneficial in individuals with serum TSH lower than 0.1 mIU/L or higher than 10 mIU/L. This article illustrates approaches to managing patients with subclinical hypothyroidism and hyperthyroidism through 5 case scenarios that apply the principles of evidence-based medicine. Because of the substantial uncertainty concerning the consequences of untreated subclinical hypothyroidism and hyperthyroidism, as well as the benefit of initiating treatment, patient preferences are important in deciding on management of subclinical disease.

Original languageEnglish (US)
Pages (from-to)239-243
Number of pages5
JournalJournal of the American Medical Association
Volume291
Issue number2
DOIs
StatePublished - Jan 14 2004

Fingerprint

Thyroid Diseases
Thyrotropin
Hyperthyroidism
Hypothyroidism
Serum
Reference Values
Patient Preference
Evidence-Based Medicine
Disease Management
Signs and Symptoms
Uncertainty
Thyroid Gland
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Subclinical Thyroid Disease : Clinical Applications. / Col, Nananda F.; Surks, Martin I.; Daniels, Gilbert H.

In: Journal of the American Medical Association, Vol. 291, No. 2, 14.01.2004, p. 239-243.

Research output: Contribution to journalArticle

Col, Nananda F. ; Surks, Martin I. ; Daniels, Gilbert H. / Subclinical Thyroid Disease : Clinical Applications. In: Journal of the American Medical Association. 2004 ; Vol. 291, No. 2. pp. 239-243.
@article{b2d8019724e34944b7702b09c68c78d4,
title = "Subclinical Thyroid Disease: Clinical Applications",
abstract = "Subclinical hypothyroidism and hyperthyroidism are diagnoses based on laboratory evaluation with few if any clinical signs or symptoms. Subclinical hypothyroidism is defined as an elevation in serum thyroid-stimulating hormone (TSH) above the upper limit of the reference range (0.45-4.5 mIU/L) with normal serum FT4 concentration; subclinical hyperthyroidism is defined as a decrease in serum TSH below the reference range with normal serum FT 4 and T3 concentrations. Though these conditions represent the earliest stages of thyroid dysfunction, the benefits of detecting and treating subclinical thyroid disease are not well established. Most persons found to have subclinical thyroid disease will have TSH values between 0.1 and 0.45 mIU/L or between 4.5 and 10 mIU/L, for which the benefits of treatment are not clearly established; treatment may be beneficial in individuals with serum TSH lower than 0.1 mIU/L or higher than 10 mIU/L. This article illustrates approaches to managing patients with subclinical hypothyroidism and hyperthyroidism through 5 case scenarios that apply the principles of evidence-based medicine. Because of the substantial uncertainty concerning the consequences of untreated subclinical hypothyroidism and hyperthyroidism, as well as the benefit of initiating treatment, patient preferences are important in deciding on management of subclinical disease.",
author = "Col, {Nananda F.} and Surks, {Martin I.} and Daniels, {Gilbert H.}",
year = "2004",
month = "1",
day = "14",
doi = "10.1001/jama.291.2.239",
language = "English (US)",
volume = "291",
pages = "239--243",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Subclinical Thyroid Disease

T2 - Clinical Applications

AU - Col, Nananda F.

AU - Surks, Martin I.

AU - Daniels, Gilbert H.

PY - 2004/1/14

Y1 - 2004/1/14

N2 - Subclinical hypothyroidism and hyperthyroidism are diagnoses based on laboratory evaluation with few if any clinical signs or symptoms. Subclinical hypothyroidism is defined as an elevation in serum thyroid-stimulating hormone (TSH) above the upper limit of the reference range (0.45-4.5 mIU/L) with normal serum FT4 concentration; subclinical hyperthyroidism is defined as a decrease in serum TSH below the reference range with normal serum FT 4 and T3 concentrations. Though these conditions represent the earliest stages of thyroid dysfunction, the benefits of detecting and treating subclinical thyroid disease are not well established. Most persons found to have subclinical thyroid disease will have TSH values between 0.1 and 0.45 mIU/L or between 4.5 and 10 mIU/L, for which the benefits of treatment are not clearly established; treatment may be beneficial in individuals with serum TSH lower than 0.1 mIU/L or higher than 10 mIU/L. This article illustrates approaches to managing patients with subclinical hypothyroidism and hyperthyroidism through 5 case scenarios that apply the principles of evidence-based medicine. Because of the substantial uncertainty concerning the consequences of untreated subclinical hypothyroidism and hyperthyroidism, as well as the benefit of initiating treatment, patient preferences are important in deciding on management of subclinical disease.

AB - Subclinical hypothyroidism and hyperthyroidism are diagnoses based on laboratory evaluation with few if any clinical signs or symptoms. Subclinical hypothyroidism is defined as an elevation in serum thyroid-stimulating hormone (TSH) above the upper limit of the reference range (0.45-4.5 mIU/L) with normal serum FT4 concentration; subclinical hyperthyroidism is defined as a decrease in serum TSH below the reference range with normal serum FT 4 and T3 concentrations. Though these conditions represent the earliest stages of thyroid dysfunction, the benefits of detecting and treating subclinical thyroid disease are not well established. Most persons found to have subclinical thyroid disease will have TSH values between 0.1 and 0.45 mIU/L or between 4.5 and 10 mIU/L, for which the benefits of treatment are not clearly established; treatment may be beneficial in individuals with serum TSH lower than 0.1 mIU/L or higher than 10 mIU/L. This article illustrates approaches to managing patients with subclinical hypothyroidism and hyperthyroidism through 5 case scenarios that apply the principles of evidence-based medicine. Because of the substantial uncertainty concerning the consequences of untreated subclinical hypothyroidism and hyperthyroidism, as well as the benefit of initiating treatment, patient preferences are important in deciding on management of subclinical disease.

UR - http://www.scopus.com/inward/record.url?scp=0345831914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345831914&partnerID=8YFLogxK

U2 - 10.1001/jama.291.2.239

DO - 10.1001/jama.291.2.239

M3 - Article

VL - 291

SP - 239

EP - 243

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 2

ER -